Provider Briefing: Aurovela Fe 24 1/20 Availability in 2026

If your patients have been reporting difficulty filling prescriptions for Aurovela Fe 24 1/20 (Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 mcg, 24/4 regimen), you're not alone. Oral contraceptive supply disruptions have been an ongoing challenge, and Aurovela Fe 24 1/20 has been particularly affected. This briefing provides the clinical context you need to manage patient expectations and prescribing decisions.

Timeline of Supply Disruptions

Understanding the history helps contextualize the current situation:

• 2022: Initial patient reports of Aurovela Fe products being unavailable at pharmacies. Some pharmacists incorrectly informed patients the product had been discontinued.
• Early 2024: FDA inspectors identified manufacturing problems at one of Aurobindo Pharma Limited's key production facilities in Hyderabad, India. Aurobindo halted production at some lines to remediate findings, impacting supply of multiple generic products.
• 2024-2025: Intermittent availability became the norm. Supply varied significantly by geography and pharmacy chain. The FDA did not list Aurovela Fe 24 1/20 on its formal Drug Shortage Database, complicating awareness among providers.
• 2026: Supply remains inconsistent. The product is still actively manufactured but distribution is uneven across the US market.

Prescribing Implications

The intermittent availability of Aurovela Fe 24 1/20 creates several clinical considerations:

Adherence and Continuity Risks

Patients who cannot fill their prescription on time face gaps in hormonal contraception, increasing the risk of unintended pregnancy. Studies consistently show that oral contraceptive effectiveness is highly dependent on consistent, daily use. Supply disruptions that cause even brief gaps can undermine adherence patterns that patients have worked to establish.

Prescription Writing Strategies

Consider these approaches to improve fill rates:

• Prescribe by generic name: Writing for "Norethindrone Acetate/Ethinyl Estradiol 1mg/20mcg, 24/4 regimen" rather than brand name gives pharmacists more flexibility to dispense available generics (e.g., Blisovi 24 Fe).
• Include DAW (Dispense As Written) judiciously: Avoid DAW codes unless the patient has a documented clinical need for a specific manufacturer's product.
• Authorize substitution: Explicitly noting that AB-rated generic substitutions are acceptable can speed up dispensing.
• Prescribe alternatives proactively: For patients with a history of fill failures, consider prescribing the most readily available equivalent.

Therapeutic Equivalents

The following are therapeutically equivalent options for Aurovela Fe 24 1/20:

• Blisovi 24 Fe (Lupin): AB-rated generic. Identical formulation: Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 mcg, 24 active + 4 Ferrous Fumarate. Generally more consistently available.
• Junel Fe 1/20 (Teva/Allergan): Same active ingredients, 21/7 regimen. Widely available. Note the shorter active phase may affect bleeding patterns.
• Microgestin Fe 1/20 (Mayne Pharma): Same active ingredients, 21/7 regimen. Broad distribution.
• Lo Loestrin Fe (AbbVie): Brand-name. Lower estrogen dose (10 mcg Ethinyl Estradiol). 24/2/2 regimen. Higher cost but consistent supply.

For a patient-facing comparison, you can direct patients to our article on alternatives to Aurovela Fe 24 1/20.

Availability Picture: Where Supply Stands

Aurobindo Pharma continues to manufacture Aurovela Fe 24 1/20. The product has not been discontinued. However, distribution is uneven:

• Chain pharmacies (CVS, Walgreens, Rite Aid) report the most frequent stockouts, likely due to centralized, automated ordering systems.
• Independent pharmacies with access to multiple wholesalers often have better luck sourcing the product.
• Mail-order and specialty pharmacies may have access to different supply channels.

Availability tools like Medfinder for Providers can help practices check real-time stock at nearby pharmacies before sending a prescription, reducing fill failures and patient frustration.

Cost and Access Considerations

Cost should not be a barrier for most patients on oral contraceptives:

• ACA mandate: Under the Affordable Care Act, most insurance plans must cover FDA-approved contraceptive methods at $0 cost-sharing. This includes all generic oral contraceptives.
• Cash prices: For uninsured patients, Aurovela Fe 24 1/20 retails for $75-$110 per pack. Discount cards (GoodRx, SingleCare) can reduce this to $8-$25.
• 340B considerations: Covered entities participating in the 340B program may find better acquisition pricing on alternatives with more stable supply.

For uninsured or underinsured patients, direct them to our guide on saving money on Aurovela Fe 24 1/20.

Tools and Resources for Your Practice

Here are practical resources to help manage the shortage:

• Medfinder for Providers: Check real-time pharmacy availability before prescribing. Reduce prior-to-fill phone calls from pharmacies.
• FDA Drug Shortage Database: Monitor for official shortage listings at accessdata.fda.gov.
• ASHP Drug Shortage Resource Center: Tracks broader oral contraceptive supply trends.
• State pharmacy boards: Some states have enacted emergency measures allowing pharmacists extended authority to substitute or extend contraceptive prescriptions during shortages.

Looking Ahead

Several factors may influence Aurovela Fe 24 1/20 supply in the coming months:

• Aurobindo remediation: The company has been addressing the manufacturing issues identified by the FDA. Completion of remediation should improve production capacity.
• Market dynamics: If demand shifts toward alternatives during the shortage, Aurovela supply may stabilize as competitive pressure eases.
• Regulatory considerations: The FDA's Drug Competition Action Plan continues to encourage additional generic entrants, though approval timelines for new oral contraceptive generics remain lengthy.

Final Thoughts

The Aurovela Fe 24 1/20 availability situation requires a proactive approach from prescribers. Writing flexible prescriptions, maintaining awareness of therapeutic equivalents, and leveraging tools like Medfinder for Providers can significantly reduce the burden on your patients and your practice.

For a practical guide on managing patient fill failures, see our article on how to help your patients find Aurovela Fe 24 1/20 in stock.